Oric Pharmaceuticals Inc
oricpharma.comOric Pharmaceuticals Inc (NASDAQ: ORIC) is a clinical-stage oncology company that discovers and develops therapies targeting cancer resistance mechanisms. The company generates no product revenue, funding operations through capital raises while advancing two lead clinical programs: rinzimetostat and enozertinib. Rinzimetostat is an allosteric inhibitor of PRC2 via the EED subunit, licensed from Mirati Therapeutics, and is in Phase 1b trials for metastatic castration resistant prostate cancer in combination with apalutamide and darolutamide, with clinical trial collaboration agreements in place with Johnson & Johnson and Bayer. Enozertinib is a brain-penetrant, orally bioavailable irreversible inhibitor targeting EGFR exon 20 and atypical EGFR mutations, licensed from Voronoi Inc., and is in Phase 1b trials for NSCLC. As of August 12, 2025, the company executed a strategic pipeline prioritization, eliminating its discovery research group to concentrate resources on these two programs.
Products & Services
Rinzimetostat (formerly ORIC-944): allosteric PRC2/EED inhibitor in Phase 1b for metastatic castration resistant prostate cancer (mCRPC), licensed from Mirati Therapeutics. Enozertinib (formerly ORIC-114): brain-penetrant irreversible EGFR exon 20 and atypical EGFR inhibitor in Phase 1b for NSCLC, licensed from Voronoi Inc.
Revenue Model
Pre-revenue clinical-stage company. Operations are funded through equity financing. No product sales or royalty income are disclosed in the filing excerpts.
Customers & Markets
End markets are oncology patients with treatment-resistant cancers, specifically mCRPC and EGFR-mutated NSCLC. No commercial customers disclosed.
Geographic Exposure
Clinical trials conducted in the United States and South Korea (enozertinib CTA filed in South Korea in Q4 2021, cleared Q1 2022). No commercial geographic footprint disclosed.
Financial Snapshot
Loading...
